Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(AURORA) A Randomized, Double-blind, Placebo-Controlled Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and Protoporphyrin IX (PPIX) Concentrations in Participants With Erythropoietic Protoporphyria (EPP)

NCT05308472 is registered in ClinicalTrials.gov with Disc Medicine, Inc as lead sponsor.

NCT NCT05308472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05308472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(AURORA) A Randomized, Double-blind, Placebo-Controlled Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and Protoporphyrin IX (PPIX) Concentrations in Participants With Erythropoietic Protoporphyria (EPP)
Lead sponsor
Disc Medicine, Inc
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2022
Completion date
August 23, 2024
Enrollment
75 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietic protoporphyria